Phase I Trial of OXIRI [Oxaliplatin (O), Xeloda (X) and Irinotecan (I)] Treatment in Patients With Advanced and/or Metastatic Pancreatic Adenocarcinoma
Latest Information Update: 06 Nov 2021
Price :
$35 *
At a glance
- Drugs Capecitabine (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms OXIRI
- 28 May 2021 Status changed from recruiting to completed.
- 25 Jan 2020 Results presented at the 2020 Gastrointestinal Cancers Symposium
- 01 May 2019 Planned End Date changed from 1 Jun 2019 to 1 Dec 2019.